Acromegaly: Correlation between expression of somatostatin receptor subtypes and response to octreotide-lar treatment

Pituitary

Volumn 12, Issue 4, 2009, Pages 297-303

  Casarini, Ana Paula M ^a   Jallad, Raquel S ^a   Pinto, Emília M ^a   Soares, Iberê C ^a   Nonogaki, Suely ^a   Giannella Neto, Daniel ^a   Musolino, Nina R ^a   Alves, Venâncio A F ^a   Bronstein, Marcello D ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Acromegaly; Octreotide; Somatostatin; Somatostatin analogs; Somatostatin receptor subtypes

Indexed keywords

ANGIOPEPTIN; GROWTH HORMONE; OCTREOTIDE; SOMATOMEDIN C; SOMATOSTATIN RECEPTOR 1; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 3; SOMATOSTATIN RECEPTOR 5;

ACROMEGALY; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; GENE EXPRESSION; GENE FUNCTION; HORMONE BLOOD LEVEL; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR VOLUME;

ACROMEGALY; ANTINEOPLASTIC AGENTS, HORMONAL; HUMAN GROWTH HORMONE; HUMANS; IMMUNOHISTOCHEMISTRY; INSULIN-LIKE GROWTH FACTOR I; OCTREOTIDE; RECEPTORS, SOMATOSTATIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SOMATOSTATIN;

EID: 70350268381     PISSN: 1386341X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11102-009-0175-1     Document Type: Article

References (52)

1. Brazeau P, Vale W, Burgus R et al (1973) Hypotalamic polypeptide that inhibits the secretion of immunoreactive pituitary growth hormone. Science 179(8):77-79. doi: 10.1126/science.179.4068.77
2. Moller LN, Stidsen CE, Hartmann B et al (2003) Review: Somatostatin receptors. Biochim Biophys Acta 1616:1-84. doi: 10.1016/ S0005-2736(03)00235-9
3. Schonbrunm A, Tashjian H Jr (1978) Characterization of functional receptors for somatostatin in rat pituitary cells in culture. J Biol Chem 253(18):6473-6483
4. Reisine T, Bell G (1995) Molecular biology of somatostatin receptors. Endocr Rev 16:427-442
5. Hofland LJ, Lamberts S (2003) The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev 24:28-47. doi: 10.1210/er.2000-0001
6. Taboada GF, Luque RM, Bastos W et al (2007) Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas. Eur J Endocrinol 156:65-74. doi: 10.1530/eje.1.02313
7. Ballare E, Persani L, Lania AG et al (2001) Mutation of somatostatin receptor type 5 in an acromegalic patient resistant to somatostatin analog treatment. J Clin Endocrinol Metab 86(8):3809-3814. doi: 10.1210/ jc.86.8.3809
8. Barlier A, Boullier LP, Gunz G et al (1999) Impact of gsp oncogene on expression of genes coding for Gsa, Pit-1, Gi2a, and somatostatin receptor 2 in human somatotroph adenomas: Involvement in octreotide sensitivity. J Clin Endocrinol Metab 84:2759-2765. doi: 10.1210/ jc.84.8.2759
9. Danila DC, Haidar JNS, Zhang X et al (2001) Somatostatin receptor-specific analogs: Effects on cell proliferation and growth hormone secretion in human somatotroph tumors. Clin Endocrinol Metab 86:2976-2981. doi: 10.1210/jc.86.7.2976
10. Elberg G, Hipkin W, Schonbrunn A (2002) Homologus and heterologus regulation of somatostatin receptor 2. Mol Endocrinol 16:2502-2514. doi: 10.1210/me.2002-0207
11. Greenman Y, Melmed S (1994) Expression of three somatostatin receptor subtypes in pituitary adenomas: Evidence for preferential SSTR5 expression in the mammosomatotroph lineage. J Clin Endocrinol Metab 79:724-729. doi: 10.1210/jc.79.3.724
12. Teijeiro R, Rios R, Costoya J et al (2002) Activation of human somatostatin receptor 2 promotes apoptosis through a mechanism that is independent from induction of p53. Cell Physiol Biochem 12:31-38. doi: 10.1159/000047824
13. Csaba Z, Dournaud P (2001) Cellular biology of somatostatin receptors. Neuropeptides 35:1-23. doi: 10.1054/npep.2001.0848
14. Freda PU, Katznelson L, Van der Lely AJ et al (2005) Long-acting somatostatin analog therapy of acromegaly: A meta-analysis. J Clin Endocrinol Metab 90:4465-4473. doi: 10.1210/jc.2005-0260
15. Jallad RS, Musolino NR, Salgado LR et al (2005) Treatment of acromegaly with octreotide-LAR: Extensive experience in a Brazilian institution. Clin Endocrinol (Oxf) 63:168-175. doi: 10.1111/j.1365-2265.2005.02317.x
16. Bronstein M, Musolino N, Jallad R et al (2005) Pharmacokinetic profile of lanreotide Autogel in patients with acromegaly after four deep subcutaneous injections of 60, 90 or 120 mg every 28 days. Clin Endocrinol (Oxf) 63:514-519. doi: 10.1111/j.1365-2265.2005.02372.x
17. Freda PU (2002) Clinical review 150: Somatostatin analogs in acromegaly. J Clin Endocrinol Metab 87(7):3013-3018. doi: 10.1210/jc.87.7.3013
18. Lamberts SWJ, Lely V, Hofland LJ (2002) New somatostatin analogs: Will they fulfil old promises? Eur J Endocrinol 146:701-705. doi: 10.1530/ eje.0.1460701
19. Petersenn S, Heynes M, Ludecke DK et al (2000) Absence of somatostatin receptor type 2A mutation and Gip ongogene in pituitary somatotroph adenomas. Clin Endocrinol (Oxf) 52:35-42. doi: 10.1046/ j.1365-2265.2000.00880.x
20. Petersenn S, Rasch AC, Bonhke et al (2002) Identification of an upstream pituitary-active promoter of human somatostatin receptor subtype 5. Endocrinology 143:2626-2634. doi: 10.1210/en.143.7.2626
21. Saveanu A, Lavaque E, Gunz G et al (2002) Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23 A 387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenomas cells. J Clin Endocrinol Metab 87:5545-5552. doi: 10.1210/jc.2002-020934
22. Saveanu A, Gunz G, Dufour H et al (2001) BIM-23244, a somatostatin receptor subtype 2 and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide - resistant human GH secreting adenomas. J Clin Endocrinol Metab 86:140-145. doi: 10.1210/ jc.86.1.140
23. Jallad RS, Musolino NR, Kodaira S et al (2007) Does partial surgical tumor removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue? Clin Endocrinol (Oxf) 67(2):310-315. doi: 10.1111/j.1365-2265.2007.02885.x
24. Antonov J, Goldstein DR, Oberli A et al (2005) Reliable gene expression measurements from degraded RNA by quantitative real-time PCR depend on short amplicons and a proper normalization. Lab Invest 85(8):1040-1050. doi: 10.1038/labinvest.3700303
25. Ponchel F, Toomes C, Bransfield K et al (2003) Real-time PCR based on SYBR-Green I fluorescence: An alternative to the TaqMan assay for a relative quantification of gene rearrangements, gene amplifications and micro gene deletions. BMC Biotechnol 13:3-18
26. Jaquet P, Saveanu A, Gunz G et al (2000) Human somatostatin receptors subtypes in acromegaly: Distinct patterns of menssenger ribonucleic acid expression and hormone suppression identify distinct tumoral phenotypes. J Clin Endocrinol Metab 85:781-792. doi: 10.1210/jc.85.2.781
27. Panetta R, Patel YC (1995) Expression of mRNA for all five human somatostatin receptors (hSSTR1-5) in pituitary tumors. Life Sci 56:333-342. doi: 10.1016/0024-3205(94)00956-2
28. Miller GM, Alexander JM, Bikkal HA et al (1995) Somatostatin receptor subtype gene expression in pituitary adenomas. J Clin Endocrinol Metab 80:1386-1392. doi: 10.1210/jc.80.4.1386
29. Greenman Y, Melmed S (1194) Heterogenous expression of two somatostatin receptor subtypes in pituitary tumors. J Clin Endocrinol Metab 78:398-403. doi: 10.1210/jc.78.2.398
30. Lamberts SW, Krenning EP, Reubi JC (1991) The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev 12:450-482. doi: 10.1210/edrv-12-4-450
31. Lamberts SW, Lely AJVL, Herder WW et al (1196) Octreotide. N Engl J Med 334:246-254. doi: 10.1056/NEJM199601253340408
32. Florio T, Thellung S, Corsaro A et al (2003) Characterization of the intracellular mechanisms mediating somatostatin and lanreotide inhibition of DNA synthesis and growth hormone release from dispersed human GH-secreting pituitary adenoma cells in vitro. Clin Endocrinol (Oxf) 59:115-128. doi: 10.1046/j.1365-2265.2003.01811.x
33. Hofland LJ, Hoek JVD, Koetsveld PMV et al (2004) The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone and prolactin secreting pituitary adenomas in vitro. J Clin Endocrinol Metab 89(4):1577-1585. doi: 10.1210/jc.2003-031344
34. Park C, Yang I, Woo J et al (2004) Somatostatin (SRIF) receptor subtype 2 and 5 gene expression in growth hormone-secreting pituitary adenomas: the relationship with endogenous SRIF activity and response to Octreotide. Endocr J 51(2):227-236. doi: 10.1507/endocrj.51.227
35. Lissett CA, Shalet SM (2000) Management of pituitary tumours: Strategy for investigation and follow-up. Horm Res 53(3):65-70. doi: 10.1159/ 000023537
36. Colao A, Ferone D, Marzullo P et al (2004) Systemic complications of acromegaly: Epidemiology, pathogenesis, and management. Endocr Rev 25:102-152. doi: 10.1210/er.2002-0022
37. Etxabe J, Gaztambide S, Latorre P et al (1993) Acromegaly: An epidemiological study. J Endocrinol Invest 16:181-187
38. Thodou E, Kontogeorgos G, Theodossiou D et al (2006) Mapping of somatostatin receptor types in GH or/and PRL producing pituitary adenomas. J Clin Pathol 59:274-279. doi: 10.1136/jcp.2005.026914
39. Ezzat S, Kontogeorgos G, Redelmeier DA et al (1995) In vivo responsiveness of morphological variants of growth hormone-producing pituitary adenomas to octreotide. Eur J Endocrinol 133(6):686-690. doi: 10.1530/eje.0.1330686
40. Van Der Lely AJ, Harris AG, Lamberts SW (1992) The sensitivity of growth hormone secretion to medical treatment in acromegalic patients: influence of age and sex. Clin Endocrinol (Oxf) 37:181-185. doi: 10.1111/ j.1365-2265.1992.tb02304.x
41. Yang IM, Woo JT, Kim SW et al (1995) Characteristics of acromegalic patients with good response to octreotide, a somatostatin analogue. Clin Endocrinol (Oxf) 42(3):295-301. doi: 10.1111/j.1365-2265.1995.tb01878.x
42. Jaquet P, Gunz G, Saveanu A et al (2005) Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy. Eur J Endocrinol 153:135-141. doi: 10.1530/eje.1.01950
43. Hofland LJ, Lamberts SW (2004) Somatostatin receptors in pituitary function, diagnosis and therapy. Front Horm Res 32:235-252. doi: 10.1159/ 000079048
44. Bronstein MD (2006) Acromegaly: Molecular expression os somatostatin receptor subtypes and treatment outcome. Front Horm Res 35:129-134. doi: 10.1159/000094315
45. Newman CB, Melmed S, George A et al (1998) Octreotide as primary therapy for acromegaly. J Clin Endocrinol Metab 83:3034-3040. doi: 10.1210/ jc.83.9.3034
46. Bevan JS (2005) The antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab 90:1856-1863. doi: 10.1210/ jc.2004-1093
47. Cozzi R, Attanasio R, Montini M et al (2003) Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results? J Clin Endocrinol Metab 88:3090-3098. doi: 10.1210/jc.2003-030110
48. Matrone C, Pivonello R, Colao A et al (2004) Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogs. Neuroendocrinology 79:142-148. doi: 10.1159/000077272
49. Zatelli MC, Piccin D, Tagliati F et al (2003) Somatostatin receptor subtype 1 selective activation in human growth hormone (GH)- and prolactin (PRL)-secreting pituitary adenomas: Effects on cell viability, GH and PRL secretion. J Clin Endocrinol Metab 88:2797-2802. doi: 10.1210/ jc.2002-021825
50. Olias G, Viollet C, Kusserow H et al (2004) Regulation and fuction os somatostatin receptors. J Neurochem 89:1057-1091. doi: 10.1111/ j.1471-4159.2004.02402.x
51. Casarini AP, Pinto EM, Jallad RS et al (2006) Dissociation between tumor shrinkage and hormonal response during somatostatin analog treatment in an acromegalic patient: Preferential expression of somatostatin receptor subtype 3. J Endocrinol Invest 29(9):826-830
52. Resmini E, Dadati P, Ravetti JL et al (2007) Rapid pituitary tumor shrinkage with dissociation between antiproliferative and antisecretory effects of a long-acting Octreotide in an acromegalic patient. J Clin Endocrinol Metab 92(5):1592-1599. doi: 10.1210/jc.2006-2084